C5AR1 and Alzheimer disease: Research by Fonseca et al. showed that the oral delivery of a cyclic hexapeptide (PMX205), another C5aR1 antagonist, for 2–3 months resulted in a substantial reduction in pathological markers such as fibrillar amyloid deposits (49–62%) and activated glia (42–68%) in two mouse models of AD [150].